Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor: Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske

Publikováno v: The Lancet Haematology. 9:e810-e821

Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0

Central venous catheter–related infections in hematology and oncology : 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Autor: Matthias Kochanek, Hans-Heinrich Wolf, Sibylle C. Mellinghoff, Meinolf Karthaus, Bernd Metzner, Boris Böll, Dieter Buchheidt, Enrico Schalk, Annika Y. Claßen, Maria J G T Vehreschild, Marcus Hentrich, Michael G. Kiehl, Markus Ruhnke, Til Ramon Kiderlen, Justin Hasenkamp, Philippe Kostrewa, Michael Koldehoff, Olaf Penack, Florian Weissinger

Publikováno v: Annals of Hematology

Cancer patients frequently require central venous catheters for therapy and parenteral nutrition and are at high risk of central venous catheter–related infections (CRIs). Moreover, CRIs prolong hospitalization, cause an excess in resource utilizat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea80d49673dcb20e398f16d65c9573
https://www.ncbi.nlm.nih.gov/pubmed/32997191

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Autor: J Hoffmann, Sabrina Inselmann, Andreas Hochhaus, Philippe Kostrewa, Ruediger Hehlmann, Kristina Sohlbach, E. Eigendorff, Martin C. Müller, Andreas Neubauer, Andreas Burchert, J Ziermann, S K Metzelder, C. Schütz, Susanne Saussele

Publikováno v: Leukemia. 29:1331-1335

A minority of chronic myeloid leukemia (CML) patients is capable of successfully discontinuing imatinib. Treatment modalities to increase this proportion are currently unknown. Here, we assessed the role of interferon alpha 2a (IFN) on therapy discon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94e895db0e101fb3be990f757f84404a
https://doi.org/10.1038/leu.2015.45

Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors

Autor: Sabine, Flommersfeld, Kristina, Sohlbach, Gabriele, Jaques, Gregor, Bein, Jörg, Hoffmann, Philippe, Kostrewa, Ulrich J, Sachs

Publikováno v: Transfusion. 55(6)

Peripheral blood progenitor cells (PBPCs) are the most common stem cell source for allogeneic transplantations. Analysis of our collection data obtained with a Spectra Optia device (Terumo) for apheresis demonstrated collection efficacies (CEs) excee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1fd15c2768e6d07bc95ba465a2921993
https://pubmed.ncbi.nlm.nih.gov/25647638

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

Autor: Tilman Bostel, Andreas Burchert, Philipp Erben, Andreas Hochhaus, Andreas Neubauer, Simone Liebler, Rüdiger Hehlmann, Martin Müller, Philippe Kostrewa

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(8)

Purpose Imatinib induces sustained remissions in patients with chronic myelogenous leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the issues of cure, long-term imatinib tolerability, and imatinib resistance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f003182f3a678262c1fc5cfebb2611ac
https://pubmed.ncbi.nlm.nih.gov/20644099